Showing results (61-70 of 107) with videos related to

Sort By:
Pageof 11
Future Oncology (London, England)|December 10, 2025
Nivolumab plus brentuximab vedotin for relapsed/refractory diffuse large B-cell lymphomaNathalie A Johnson, Pier Luigi Zinzani, Eva Domingo-Domenech, et al.
Blood|July 24, 2019
Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphomaDeborah M Stephens, Hongli Li, Heiko Schöder, et al.
Blood|July 16, 2016
Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapyVindi Jurinovic, Robert Kridel, Annette M Staiger, et al.
Blood|February 23, 2022
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohortConstantine S Tam, John N Allan, Tanya Siddiqi, et al.
Blood Advances|October 23, 2023
Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemiaBrian T Hill, Shuo Ma, Clive S Zent, et al.
Blood|March 13, 2016
Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHLPaul M Barr, Gene B Saylors, Stephen E Spurgeon, et al.
American Journal of Hematology|September 13, 2019
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphomaTalha Munir, Jennifer R Brown, Susan O'Brien, et al.
British Journal of Haematology|May 3, 2019
Multicentre retrospective study of intravascular large B-cell lymphoma treated at academic institutions within the United StatesMarcus Geer, Emily Roberts, Maryann Shango, et al.
Leukemia & Lymphoma|August 19, 2015
Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomasBeata Holkova, Maciej Kmieciak, Prithviraj Bose, et al.
Leukemia|January 30, 2023
A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemiaChristine E Ryan, Danielle M Brander, Paul M Barr, et al.
Pageof 11